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2ABSTRACT
Tissue-specific ion suppression is an unavoidable matrix effect in MALDI mass 
spectrometry imaging (MSI), the negative impact of which on precision and accuracy in 
quantitative MALDI-MSI can be reduced to some extent by applying isotope internal 
standards for normalization and matrix-matched calibration routines. The detection sensitivity 
still suffers, however, often resulting in significant loss of signal for the investigated analytes. 
An MSI application considerably affected by this phenomenon is the quantitative spatial 
analysis of central nervous system (CNS) drugs. Most of these drugs are low molecular 
weight, lipophilic compounds, which exhibit inefficient desorption and ionization during 
MALDI using conventional polar acidic matrices (CHCA, DHB). Here, we present the 
application of the (2-[(2E)-3-(4-tert-butylphenyl)-2-methylprop-2-enylidene]malononitrile) 
matrix for high sensitivity imaging of CNS drugs in mouse brain sections. Since DCTB is 
usually described as electron-transfer matrix, we provide a rationale (i.e. computational 
calculations of gas-phase proton affinity and ionization energy) for an additional proton-
transfer ionization mechanism with this matrix. Furthermore, we compare the extent of signal 
suppression for five different CNS drugs when employing DCTB versus CHCA matrices. The 
results showed that the signal suppression was not only several times lower with DCTB than 
with CHCA, but also depended on the specific tissue investigated. Finally, we present the 
application of DCTB and ultra-high resolution Fourier-transform ion cyclotron resonance 
mass spectrometry to quantitative MALDI imaging of the anesthetic drug xylazine in mouse 
brain sections based on a linear matrix-matched calibration curve. DCTB afforded up to 100-
fold signal intensity improvement over CHCA when comparing representative single MSI 
pixels, and > 440-fold for the averaged mass spectrum of the adjacent tissue sections. 
Keywords: DCTB; 2-[(2E)-3-(4-tert-butylphenyl)-2-methylprop-2-enylidene]malononitrile; 
mass spectrometry imaging; MALDI; FTICR; CNS drugs; xylazine 
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3INTRODUCTION
Disorders affecting the central nervous system (CNS) are growing faster than any 
other disease, while progress in drug development in this area continues to be slow.
1,2
 This
has many reasons including the high complexity of the brain, the frequent occurrence of side 
effects with CNS drugs, and above all, the prerequisite for drugs to cross the blood-brain 
barrier (BBB).
3,4
 The latter requirement has limited the current CNS drug portfolio
predominantly to a small group of low molecular weight lipophilic compounds that can cross 
the BBB via transcellular passive diffusion (according to the Lipinski’s rule of 5),
5–7
 even
though new developments in carrier-mediated transport using liposomes
8
 or nanoparticles
9,10
are of great interest and will potentially play a significant role in the longer perspective. 
One of the most essential information at the early stages of drug discovery is the 
drug’s and its metabolites’ distribution in the whole body, which provides insight into the 
drug’s toxicity as well as its ability to reach the therapeutically desired organ/tissue or target 
receptors.
11,12
 Measuring the drug’s blood/plasma concentrations does not necessarily deliver
adequate information about its organ/tissue distribution
13
. This is even relevant for the brain,
as it is tightly isolated by the BBB; the drug distribution into the cerebrospinal fluid (CSF) is 
not a measure of BBB permeability into the brain parenchyma, but only through the blood-
CSF barrier (BSCF).
14
 Consequently, analytical tools are urgently needed to quantitatively
trace the drugs’ spatial distributions in tissue sections, particularly brain sections for CNS 
drugs. 
Over the last decade, mass spectrometry imaging (MSI) has gained wide acceptance as 
a label-free molecular imaging technique in drug distribution studies, providing considerable 
advantages over radiolabeled methods such as (quantitative) whole-body autoradiography 
((Q)WBA).
15,16
 In addition, MSI allows for obtaining the information simultaneously from the
parent drugs and its metabolites, as well as combining it with spatiotemporal changes in the 
metabolomic/lipidomic profiles.
17
 Another important advantage of MSI is that it can provide
reliable quantitative information on the amount of drug in the examined sections.
18–20
 Of all
MSI ionization techniques, matrix-assisted laser desorption/ionization (MALDI) is the most 
popular,
21–25
 particularly for imaging of pharmaceuticals.
26,27
 A number of recent review
articles have summarized the state-of-the-art of the topic.
28–32
One of the most promising applications for MSI is the measurement of the spatial 
distribution of xenobiotics in CNS tissue.
33
 A number of studies have described CNS spatial
distribution of different drugs,
34,35,44–46,36–43
 narcotics,
47–49
 neurotoxin
50
 and positron emission
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4tomography (PET) ligands.
51
 Two recent studies reported more sophisticated uses of MALDI-
MSI, including studying drug-drug interactions and their impact on the BBB permeability,
52
and amyloid-binding molecules in an experimental model of Alzheimer's disease.
53
 Both
examples provide an outlook to the future of MSI in the CNS pharmacology field.
54
Although (MALDI-)MSI has proved its usefulness in pharmacology, several factors 
still limit its wider applicability to CNS drugs, which are predominantly linked to sensitivity 
issues. Firstly, MSI is a “sample volume limited” technique, in which the effective limits of 
detection and quantification will strongly depend on the employed pixel size (irradiated single 
spot area).
55
 This is further amplified by the aforementioned low permeability through the
BBB that limits the amount of drug in the CNS parenchyma. Secondly, (MALDI-)MSI suffers 
significantly from the presence of tissue-specific ion suppression that cannot be entirely 
avoided since no separation step is implemented prior to ionization (in contrast to GC- or LC-
MS).
56–58
 While its negative impact on precision and accuracy in quantitative MALDI-MSI
can be limited to some extent by applying isotope internal standards for normalization and 
matrix-matched calibration routines,
19,20
 the detection capabilities still suffer from this
phenomenon, often resulting in a significant loss of signal for the investigated analytes.
39,59,60
As a result, MSI of tissue in its native state (in situ) has to rely on alternative strategies. 
Among the simple strategies are changing the polarity of ionization as well as surface 
chemical treatments, such as washing the tissue with different solvents, for improving signal 
intensities for proteins,
61
peptides,
62
lipids,
63
small metabolites
64
and drugs.
46,65
Another 
approach relied on using different salt additives that minimize negative ion suppression 
effects between different classes of lipids, as shown by Popkova and Schiller
66
 or Griffiths
and Bunch
67
 for MALDI-MS, as well as by Sugiyama et al.
68
 for MALDI-MSI. Other
methods used improved matrix deposition techniques such as matrix-coating assisted by an 
electric field (MACEF)
69
 or matrix spraying by utilizing ultrasonic atomizing tablet and a
simple mini-humidifier.
70
 Furthermore, improved selectivity toward selected compound
classes by increasing ionization efficiency has been demonstrated for MALDI, by using 
alternative ionizing agents (e.g. ionizing cholesterol in a form of silver adducts)
71
, applying
on-tissue derivatization reactions
72
 or even by simply utilizing different MALDI matrices
such as, for example, nanoparticle-based inorganic matrices in surface-assisted laser 
desorption/ionization (SALDI).
73
 Surprisingly, despite the intensive research on new matrices,
the most common method for matrix selection is still the empirical testing of the most popular 
(or readily available) compounds. Consequently, despite the aforementioned physicochemical 
properties of CNS drugs (small lipophilic molecules with low polar surface area and limited 
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5hydrogen bonding
5–7
), virtually all MALDI-MSI studies of these pharmaceuticals use the two
most common polar and acidic matrices, α-cyano-4-hydroxycinnamic acid 
(CHCA)
36,39,44,48,50,51,59,74
 and 2,5-dihydroxybenzoic acid (DHB).
35,38,49,52,53,39–43,45–47
In this study, we successfully applied the nonpolar DCTB (2-[(2E)-3-(4-tert-
butylphenyl)-2-methylprop-2-enylidene]malononitrile) matrix for high sensitivity imaging of 
CNS drugs in mouse brain sections. DCTB has been frequently used as an electron-transfer 
matrix. We performed computational calculations of gas-phase proton affinity and ionization 
energy to explain the efficient, additional proton-transfer ionization mechanism with this 
matrix for five selected CNS drugs. Furthermore, using tissue extinction coefficients (TEC), 
we compared the extent of signal suppression for CNS drugs when employing DCTB versus 
CHCA matrices as well as tissue-specific ionization suppression. Finally, we applied DCTB 
for highly sensitive, quantitative MALDI imaging of the anesthetic drug xylazine within 
mouse brain sections using normalization to an isotope-labeled internal standard and a tissue-
matched calibration curve.
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6EXPERIMENTAL SECTION 
Chemicals and reagents. Xylazine, imipramine and clozapine were purchased 
from Santa Cruz Biotechnology (Heidelberg, Germany). Ketamine, clonidine, xylazine-d6 
(internal standard), α-cyano-4-hydroxycinnamic acid (CHCA), 2,5-dihydroxybenzoic acid 
(DHB), trans-2-[3-(4-tert-butylphenyl)-2-methyl-2-propenylidene]malononitrile (DCTB), 
methanol, acetonitrile, dichloromethane and standard microscopy glass slides were from 
Sigma-Aldrich (Steinheim, Germany). Rabbit brain was obtained from a local butcher store. 
Purified water was generated by a Millipore (Bedford, MA, USA) purification system. 
Animals, tissue preparation and histological staining. C57BL/6 mice
(12-week old) were purchased from Charles River (Sulzfeld, Germany). Xylazine/ketamine 
anesthesia was performed by injecting the following mixture: Rompun (0.5 mL), Ketavet (1 
mL) and 0.9% NaCl (8.5 mL); the dose was calculated per body weight (0.1 mL per 10 g 
body weight). Deep isoflurane anesthesia (negative control) was carried out by inhalation of 
5% isoflurane in oxygen. Animals were perfused with saline to remove the blood from the 
organism. Permission for the mouse perfusion was obtained from the local research ethics 
committee. The organs were dissected immediately after the sacrifice, snap-frozen in liquid 
nitrogen and stored at -80 ºC until sample preparation. The coronal brain tissue sections were 
prepared at 14 µm thickness using a Reichert Jung 2800 Frigocut cryostat microtome (Leica 
Microsystems, Wetzlar, Germany), thaw-mounted onto plain microscope glass slides and 
dried for 30 min in a vacuum desiccator. The tissues were stored at -80 ºC for no longer than 2 
d prior to MSI. After MALDI-MSI, the glass slides were washed with 70% ethanol to remove 
the matrix. The tissue sections were stained with regressive hematoxylin and eosin (H&E) and 
scanned using an Olympus slide optical microscope with an UPLANSAPO 40x/0.90 objective 
(Olympus, Tokyo, Japan). Rabbit brain (for ‘unified brain’ preparation) was homogenized 
using a Potter-Elvehjem tissue grinder (Sartorius, Göttingen, Germany), transferred into 15 
mL conical centrifuge tubes and snap-frozen in liquid nitrogen. The resulting tissue blocks 
were sectioned, mounted and dried at the same conditions as the native mouse brain tissues. 
MALDI matrix and internal standard deposition. MALDI matrices and 
internal standard were homogenously sprayed onto the tissue sections using an automated 
home-built sprayer as previously described.
75
 Solutions of CHCA (5 mg/mL in ACN/H2O,
70/30 [v/v]), DCTB (10 mg/mL in DCM/MeOH, 50/50 [v/v]) and xylazine-d6 (1 µM in 
MeOH) were freshly prepared prior to deposition. For TEC experiments, the mixture of 5 
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7CNS drugs in MeOH (at relatively high concentrations of 100 µM, to obtain a signal from all 
compounds with both matrices) was sprayed prior to matrix deposition with increasing flow 
rate in the following patterns: 2 layers at 20 µL/min, 2 layers at 40 µL/min and 4 layers at 60 
µL/min. For the final imaging experiments, internal standard (xylazine-d6) was sprayed prior 
to the matrix deposition in 6 layers at 20 µL/min. For both CHCA and DCTB matrices, 6 
layers were sprayed with increasing flow rate in the following patterns: 2 layers at 20 µL/min 
and 4 layers at 40 µL/min. The estimated amount of matrix added to the tissue (matrix 
density) was calculated at 0.0167 and 0.0334 mg/mm
2
 for CHCA and DCTB, respectively. In
addition, in-depth visual inspection of the obtained MALDI matrix layers was performed 
using scanning electron microscopy (SEM) images, which revealed excellent homogeneity 
and reproducibility as well as crystal sizes down to 1 µm for both CHCA and DCTB matrices 
(Figure S-1, SI). 
Limits of detection and limits of quantification:  Limits of detection 
(LOD) and quantification (LOQ) were adapted from generally-accepted guidelines for LC-
MS method development, to suit the quantitative MALDI-MSI data. Since a mass spectrum 
collected from a single MSI pixel corresponds to a single injection LC/MS run, the sampling 
of the entire single calibration spot provided sufficient averaging of multiple analyte 
measurements. Here, each calibration area provided 100-150 laser ablation spots, which far 
exceeded the number of technical replicates (=injections) of one calibration solution in 
LC/MS. LOD was obtained from replicate analysis of multiple blank spots (n=5, of which 
every spot contained at least 100 laser shots = single mass spectra) and calculation of the 
standard deviation (SD). LOD was defined as the analyte concentration giving a signal equal 
to the blank signal plus 3× SD of the blank. LOQ was defined as the lowest concentration of a 
sample that can be quantified with acceptable precision (coefficient of variation, CV≤20%) 
and bias (±20%). CV was measured within the single calibration spot (showing dispersion of 
drug signal intensity values of >100 single MSI pixels) and bias was calculated for the single 
spot from the calibration curve. 
Mass spectrometry and data analysis. MALDI experiments were performed 
in positive ion mode on a Bruker (Bremen, Germany) 7 Tesla Solarix FTICR mass 
spectrometer, equipped with a dual ESI/MALDI ion source and Smartbeam II Nd:YAG (355 
nm) laser. MALDI imaging data were collected either in a full scan mode from m/z 50 to 
1,000 (for TEC experiments) or in CASI (continuous accumulation of selected ions) mode 
with a 100 u wide isolation window, set in the quadrupole, centered on m/z 225 with transient 
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8length of 1.0486 s and resolving power (FWHM) of ~317,000 at m/z 220. Internal mass 
calibration was performed using either a series of peaks originating from the MALDI matrix 
(TEC experiments) or a lock mass from the internal standard signal (xylazine imaging 
experiments). MSI pixel size settings were: 100 µm for the final imaging of xylazine from 
dosed animals, which assured dense pixel deposition and avoided overlap between 
neighboring laser spots, and 150 µm for TEC experiments (to reduce the time of the entire 
experiment). For all MALDI-MS and MALDI-MSI experiments, the laser was set to the 
“small” spot size and the repetition rate to 1 kHz. For experiments performed with CHCA and 
DHB, the laser power was set to 20 % and the number of laser shots/pixel to 200, while for 
the experiments with DCTB, the laser power was set to 15 % and the number of laser 
shots/pixel to 50. MALDI experiments with standards were carried out by using dried-droplet 
sample preparation onto steel MALDI target plates (Bruker), and collecting and co-adding 16 
individual transients for each mass spectrum from three MALDI spots, assuring correction for 
intra- and inter-spot variabilities. All MS/MS experiments were performed by isolation of 
precursor ions in the external quadrupole (isolation window: 5-10 u) and accumulation in the 
hexapole for collision-induced dissociation (CID) at varying collision energies (15-25 V). 
Data were processed and analyzed using the Bruker Data Analysis and FlexImaging software 
programs for single mass spectra and imaging data sets, respectively. For quantitative MALDI 
imaging of xylazine, a series of seven different calibration standard solutions was spotted onto 
the blank “unified brain” slices, followed by internal standard and DCTB matrix spraying. 
MALDI-MSI experiments were conducted using the same experimental conditions as for the 
native brain tissues. Finally, calibration curves were performed by extracting the imzML
76
files from FlexImaging and processing with the open-source MSiReader software.
77
Computational Experiments. Physicochemical properties (pKa and clogD) of 
five selected CNS drugs were predicted with ACD/PhysChem Suite (version 14.0, Advanced 
Chemistry Development, Toronto, ON, Canada, 2016). Calculations of gas phase 
deprotonation enthalpies (DPE) and gas phase proton affinities (PA) were performed utilizing 
B3LYP/6-311+G(2df,p)//B3LYP/6-31G(d) level of theory. This computational model has 
been confirmed as a reliable method for calculation of PA and DPE, giving values that were 
in good agreement with the experiment.
78
 However, since the accuracy of the B3LYP method
is not satisfactory for calculation of ionization energies (IE),
79
 the MP2/6-
31+G(2df,p)//MP2/6-31G(d) approach was applied for this purpose. All calculations were 
performed with the Gaussian 09 program package.
80 
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9RESULTS AND DISCUSSION 
Rationale for Proton-transfer MALDI with DCTB Matrix. DCTB is 
well-known for its efficient desorption/ionization capabilities at low laser fluences, which has 
been linked to its high molar absorption coefficient.
81
 Its application range is somewhat
limited, predominantly for analysis of polymers
82
, fullerens
83
, organometallics
84
 and more
recently nanoparticles and nanoclusters
85
. DCTB’s mode of action in these applications is that
of an aprotic, electron-transfer (ET) secondary reaction matrix, delivering primarily radical 
ions in positive ion mode, or, when purposely forced, cationized molecules of the investigated 
compounds. This mechanism of action was previously investigated in detail by Wyatt et al. 
for different classes of compounds.
86
Interestingly, experiments conducted in our laboratory revealed that DCTB appears 
equally suited as proton-transfer (PT) matrix, which prompted us to investigate a mechanistic 
rationale for this additional transfer mechanism. Since both current MALDI models (gas 
phase protonation and “Lucky Survivor” model) require an excess of protonated matrix ions 
for efficient MALDI analyte protonation,
87
 it was important to study the MALDI mass
spectrum of pure DCTB in positive ion mode (Figure 1A). The spectrum exhibited two major 
ions, which were identified as the protonated molecule [M + H]
+
 and a radical cation after
methyl loss [M – CH3]
+·
. In addition, low intensity signals from the radical cation M
+·
 and a
somewhat unexpected [M – H]
+
 ion were also observed. The relative intensities of radical
versus protonated DCTB signals depended on the laser fluence, with the latter more 
prominent at lower energies. Furthermore, as the secondary reactions occurring in the 
expanding MALDI plume are believed to occur under thermodynamic rather than kinetic 
control,
88
 we also performed computational calculations of gas-phase proton affinities (PA).
PA has been shown to determine the resulting MALDI mass spectra in positive ion mode as 
well as the ionization efficiencies observed for the chemical matrices.
89
 The low proton
affinity of DCTB (see Figure 1), which is only slightly higher than that of CHCA and 
significantly lower than the two drugs studied here (xylazine and ketamine), suggests that 
secondary proton-transfer reactions between protonated matrix and neutral analyte are 
thermodynamically possible. These findings were confirmed by analyzing an equimolar 
mixture of the two drugs with DCTB, where protonated ketamine and xylazine signals were 
readily observed, the latter of which exhibited higher intensity due to the higher PA. 
Interestingly, the same experiments performed with two different MALDI matrices (CHCA 
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versus DCTB) also revealed ion species of these drugs other than protonated molecules such 
as radical ions as well as sodium and/or potassium adducts. Their intensities, however, were 
always significantly lower than those of the protonated molecules (relative abundances, 
≤1%). Moreover, the relative intensity ratio of radical-to-protonated drug species was higher 
for DCTB than for CHCA. This suggests a mixed mechanism of DCTB-assisted laser 
desorption/ionization, with the proton-transfer clearly being the dominant pathway. Of note, 
the additionally calculated IE confirmed the less favorable nature of potential ET reactions 
between radical cation of matrix and neutral analyte. Moreover, calculation of DCTB gas-
phase acidities (deprotonation enthalpy, DPE = 1469 kJ/mol versus 1382 kJ/mol for CHCA 
and 1448 kJ/mol for acetic acid) revealed the acidic character of the methyl group attached to 
the aliphatic chain of DCTB. This finding is in agreement with NMR data presented by 
Gabriel et al.,
90
 who reported the highly acidic character of this methyl group, in contrast to
the widely accepted aprotic description of DCTB. These data together with the 
abovementioned findings support an additional proton-transfer ionization mechanism of 
DCTB as MALDI matrix. 
MALDI Matrix-dependent Tissue-specific Ion Suppression. To assess 
the usefulness of DCTB as nonpolar MALDI matrix for low molecular weight lipophilic CNS 
drugs, we selected five model compounds (Figure 2), representing different fields of 
neuropharmacological application: xylazine (veterinary tranquilizer/anesthetic), ketamine 
(drugs of abuse, but also promising as rapid and potent antidepressant), clonidine (anxiety 
disorder and withdrawal syndrome therapeutic), imipramine (tricyclic antidepressant), and 
clozapine (atypical antipsychotic treatment for schizophrenia). All selected compounds have 
molecular weights in the range of 200-400 g/mol and are predominantly in their neutral forms 
at physiological pH of blood and brain; consequently, the calculated distribution coefficients 
clogD at pH 7.4 are between 1 and 3 (Figure 2), thus confirming the liphophilic character at 
these conditions. 
In the first set of experiments, we conducted MALDI-FTICR analyses. As can be seen 
in Figure 3A, CHCA matrix provided the highest signal intensities. The same drugs mixed 
with brain extract (obtained from isoflurane anesthetized mouse according to a modified 
protocol
91
) to indicate the presence of potentially suppressing endogenous compounds
exhibited the highest signal intensities when DCTB matrix was used (Figure 3B). This 
provided strong evidence for considerably lower signal suppression from endogenous brain 
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tissue-related compounds with nonpolar DCTB matrix as compared to CHCA and DHB. DHB 
gave significantly lower signal intensities and also suffered from limitations of spatial 
resolving power due to the large crystals formed during spraying (see SEM images in Figure 
S-1, SI). In all further experiments, we therefore limited all further comparisons to CHCA 
versus DCTB. 
To further validate these findings for MALDI-MSI, we employed the tissue extinction 
coefficient (TEC) technique developed by Stoeckli et al.,
59
 which was later expanded by
Hamm et al.
39
 Recently, Taylor et al. implemented TECs for systematic comparison of DESI
and MALDI (with CHCA matrix)-related ion suppression of uniformly deposited olanzapine 
from heterogeneous transverse brain sections.
60
 For the TEC experiments, an equimolar
mixture of five CNS drugs was sprayed onto the glass slide containing the three thaw-
mounted negative control (isoflurane anesthetized) brain coronal sections, followed by 
MALDI-FTICR-MSI (see Experimental Section). As reference, the off-tissue glass region of 
interest was selected and imaged with the same experimental conditions. The final TEC 
values were calculated based on the relationship TEC=IA,tissue/IA,ref, where IA are the averaged 
analyte ion currents on tissue and reference areas, TEC=1 represents no suppression and 
TEC=0 corresponds to total drug signal extinction. The results in Figure 4 show as much as 8-
fold less suppression with DCTB in comparison to CHCA and thus provide strong evidence 
for matrix-dependent, tissue-specific ionization suppression. Furthermore, closer investigation 
of the ion images of the five CNS drugs (Figure S-2, SI) revealed a heterogenous pattern of 
drug signals suppression (white versus grey matter), which was further underpinned by 
comparisons of mean mass spectra of the whole brain sections for the two matrices (see 
Figure S-3, SI). 
In conclusion, while the current results may not provide a complete explanation of the 
improved performance of DCTB for MALDI imaging of the investigated CNS drugs from 
brain sections in comparison to CHCA, some initial positive conclusions can be drawn. 
DCTB clearly showed increased selectivity toward lipophilic CNS drugs as well as higher 
“resistance” to brain-specific ionization suppression phenomena from endogenous compounds 
such as salts, metabolites, lipids etc. as compared to CHCA. While the organic solvent used 
for dissolving DTCB may provide more efficient extraction of neutral analytes in comparison 
to CHCA, this does not explain the observed differences, because the lower signal 
suppression levels of DCTB were observed not only during MALDI-MSI of tissue sections 
but also from MALDI-MS analysis of bulk solutions containing the same interfering 
substances from the brain tissue extract. Unfortunately, it was not possible to fully clarify 
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whether the observed effects were related to favorable desorption and gas-phase protonation 
of the investigated analytes or whether they result from physicochemical processes such as 
more efficient incorporation of non-ionized lipophilic drugs and/or less efficient incorporation 
of endogenous interfering metabolites/lipids into the non-polar DCTB matrix crystals. Further 
work on this topic is ongoing in the present authors’ laboratory. 
Xylazine Spatial Distribution in Mouse Brain Sections using Ultra-
high Resolution FTICR-MSI. The utility of DCTB for MALDI-MSI of lipophilic CNS 
drugs was demonstrated using native brain tissues of drug-dosed animals (single dose 
anesthesia with a mixture of xylazine/ketamine, see Experimental Section). The intense 
signals detected from xylazine were assigned based on accurate mass measurements and on-
tissue collision-induced dissociation (CID) experiments by comparison to the drug standard 
and previously reported fragmentation patterns (Figure S-4, SI).
92
 We then conducted two
MALDI-MSI experiments on consecutive coronal brain sections at spatial resolution of 100 
µm. As illustrated in Figure 5, tissue examined with CHCA matrix showed virtually no 
signals from xylazine, whereas tissue sprayed with DCTB matrix clearly revealed the spatial 
distribution of the drug (normalized to isotope-labeled internal standard). Since the examined 
tissue section clearly shows anatomical regions in the H&E stain of the brain, the MS ion 
image of evenly sprayed xylazine-d6 provided additional evidence for regional ion 
suppression, with the protonated xylazine molecule clearly less suppressed in the region of 
deep cerebral white matter as compared to the cerebral cortex, hippocampus, thalamus and 
hypothalamus (Figure 6). 
Furthermore, to quantify the differences observed for the two matrices, single MSI 
pixel mass spectra from representative regions of the highest xylazine abundance were 
compared, showing more than 100-fold higher signal intensity obtained with DCTB over 
CHCA. Moreover, when the average mass spectra from the whole examined tissue sections 
were compared, >440-fold signal improvement was achieved with DCTB versus CHCA. 
Importantly, the ultra-high resolving power of the Fourier-transform ion cyclotron resonance 
mass spectrometer used here played a significant role in this comparison, since a DCTB-
derived interfering ion signal was visible only 0.003 u adjacent to protonated xylazine. This 
interference had practical implications on the direct on-tissue quantification of xylazine (see 
next section). In addition to xylazine, we also interrogated the MSI data sets for the second 
administered anesthetic, ketamine as well as for potential metabolites of both drugs. As shown 
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in the previous section, ketamine exhibited much lower ionization efficiency in comparison to 
xylazine and was therefore not detected in the imaging experiments. Equally, we did not 
observe any of the reported biotransformation products of xylazine
92
 or ketamine.
93
On-tissue Quantification of Xylazine. Since most pharmaceutical MALDI-
MSI studies require absolute quantification of the investigated compounds directly from the 
tissue surfaces, we also implemented the DCTB matrix for this purpose. Obtaining reliable 
quantitative results with MALDI-MSI requires normalization to isotopically-labeled internal 
standard (xylazine-d6) and matrix-matched calibration routines. The best results for the latter 
are usually obtained by using either the sophisticated “mimetic tissue” model or a simpler 
“on-tissue” approach.
20
 Here, we combined both strategies (the workflow is presented in
Figure S-5, SI). Briefly, rabbit brain was homogenized and snap-frozen in liquid nitrogen for 
the best possible emulation of the original intact tissue morphology, as previously reported by 
Jadoul et al.
94
 The prepared blocks of “unified brain” tissue (containing a representation of the
interfering endogenous compounds from different anatomical brain regions) were then cut 
with the cryomicrotome and served as large and convenient blank sections for the fast “on-
tissue” spiking approach. 
This approach generated linear relationships (coefficients of determination, R
2
 =
0.996) over a wide concentration range of the calibration curve (almost three orders of 
magnitude, see Figure S-5, SI). The limits of detection (LOD, estimated from multiple blank 
measurements) and limits of quantification LOQ, (based on a precision of the measurements 
of 20% or better, and calculated bias values for the lowest concentrated calibration solution 
within 80-120%) were 0.629 µg/g and 3.14 µg/g, respectively (assuming average brain 
density of 1.027 g/cm
3
).
95
 Finally, the average absolute concentration of xylazine across the
mouse brain coronal section illustrated in Figure 5-B was calculated to be 21.75 ± 0.41 
µg/gtissue. The relatively large confidence interval of the mean was calculated based on the 
standard deviation of all scans (scan number, n = 4255), averaged across the whole tissue 
section; therefore, it reflects the heterogeneity of xylazine distribution in the brain section. 
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CONCLUSIONS
The primary aim of this study was the application of the non-polar DCTB compound 
as MALDI matrix for high sensitivity imaging of CNS drugs in mouse brain sections. Based 
on five selected neuropharmaceuticals, which all fulfilled the requirements for crossing the 
blood-brain barrier via transcellular passive diffusion (i.e., Lipinski’s rule of 5), we 
demonstrated that DCTB can be successfully used for high sensitive MALDI mass spectral 
imaging of these compounds from murine brain sections using an ultra-high resolution 
Fourier-transform ion cyclotron resonance (FTICR) platform. We provided a theoretical and 
experimental rationale for an additional proton-transfer ionization mechanism of the DCTB 
matrix, even though DCTB is usually considered an electron-transfer matrix. We also 
investigated tissue specific ion suppression for DCTB versus the conventional polar and 
acidic CHCA matrix, based on tissue extinction coefficients (TEC). These experiments 
showed multi-fold lower signal suppression for the drugs using DCTB than CHCA. 
Furthermore, we applied DCTB for quantitative imaging of a commonly used veterinary 
anesthetic drug, xylazine from mouse coronal brain sections. Compared to CHCA, the data 
showed significant signal intensity improvements by as much as 100-fold for representative 
single MSI pixels of two serial sections and more than 440-fold for an average mass spectrum 
from the whole adjacent tissue sections. Finally, the application of tissue-matched 
standardization allowed for excellent linearity of the calibration curve over a wide 
concentration range with satisfactory precision. 
The use of the DCTB matrix was not without challenges, however, including 
difficulties linked to the low melting point (~130 °C versus ~249 °C for CHCA), i.e. limited 
stability under high vacuum conditions (which was overcome by normalization to 
homogenously sprayed internal standard) and the “volcano” type ablation profiles, which can 
constitute a challenge for higher spatial resolutions than used here. We did not observe any 
formation of adducts between DCTB and drugs as previously described by Lou et al.
96
Our future work will focus on improving the DCTB matrix solubility and stability 
under high vacuum conditions. Other work currently in progress includes a detailed 
investigation of the tissue-specific ionization suppression of different drugs when using 
different MALDI matrices, which will further improve the detection capabilities of MALDI-
MSI for other pharmaceutical drugs. 
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Figure 1. (A) Representative MALDI-FTICR mass spectrum of pure DCTB matrix after 
dried-droplet sample preparation. (B) Computationally-derived proton affinities (PA) and 
ionization energies (IE) for CHCA and DCTB matrices, as well the two CNS drugs (xylazine 
and ketamine). 
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Figure 2. Chemical structures of the five CNS drugs investigated in this study, along with 
molecular weights and calculated, pKa and clogD values (at physiological pH of 7.4). 
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Figure 3. Bar chart showing signal intensities for (A) standard solutions of five CNS drugs 
obtained by MALDI-FTICR after dried-droplet sample preparation using DHB, CHCA and 
DCTB matrices; (B) standard solutions spiked into mouse brain extract. (Error bars represent 
standard deviation, SD (n=3); 16 transients from at least 3 different MALDI spots for inter- 
and intra-spot variability correction were collected of the individual drug standards (10 µM) 
with dried-droplet sample preparation.) 
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Figure 4. Bar chart (A) and numerical values (B) of tissue extinction coefficients (TEC) 
calculated for five CNS drugs based on the MALDI-FTICR imaging experiments performed 
with CHCA and DCTB matrices. 
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Figure 5. Spatial distribution of xylazine in mouse brain coronal sections obtained from 
MALDI-FTICR imaging experiments performed on two consecutive sections with two 
different MALDI matrices, CHCA (A) and DCTB (B), along with single MSI pixel mass 
spectra extracted from representative regions of the highest abundance of xylazine detected 
with CHCA (C) and DCTB (D). MSI pixel size: 100 µm. Scale bars: 2 mm. 
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Figure 6. MS ion image (not normalized) of the evenly-distributed internal standard 
(xylazine-d6) on brain coronal section obtained from xylazine-anesthetized mouse (A); two 
expanded sub-regions (hippocampus and deep cerebral white matter) (B) showing clear 
evidence for brain sub-region specific ion suppression of the deuterated drug signal. MSI 
pixel size: 100 µm. (C) MS ion images of the evenly-distributed xylazine standard on brain 
coronal section obtained from isoflurane-anesthetized mouse showing superior performance 
of normalization against isotope-labeled internal standard (IS) in comparison with two other 
common strategies (TIC and RMS). MSI pixel size: 100 µm. 
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